Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24727287 | 0.91 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3TP53 | |
| SCHEMBL3184997 | 0.86 | DHFR (0.53) | SLC6A2SLC6A4SLC6A3DHFRHRH3 | |
| SCHEMBL11937237 | 0.85 | DHFR (0.46) | SLC6A2SLC6A4SLC6A3DHFRHSD11B1 | |
| SCHEMBL5642512 | 0.82 | DHFR (0.48) | SLC6A2SLC6A4SLC6A3DHFRHRH3 | |
| SCHEMBL29642714 | 0.82 | DHFR (0.48) | SLC6A2SLC6A4SLC6A3DHFRHRH3 | |
| SCHEMBL1714946 | 0.81 | LTA4H (0.40) | DHFRKMT2AMEN1HSD11B1TEAD1 | |
| SCHEMBL8321729 | 0.81 | DHFR (0.47) | SLC6A2SLC6A4SLC6A3DHFRHRH3 | |
| SCHEMBL24168852 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HRH3TP53 | |
| SCHEMBL5546439 | 0.79 | DHFR (0.48) | DHFRHRH3KMT2AMEN1HSD11B1 | |
| SCHEMBL1025178 | 0.79 | DHFR (0.54) | DHFRTP53TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642763-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | claimed |
| WO-2024141534-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | claimed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642763-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024141534-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141534-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| EP-3860994-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | The University of British Columbia (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020069625-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-09 | — | — | WO | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | SLC6A2 2077/4885SLC6A4 1737/4885SLC6A3 1955/4885 |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | SLC6A2 4377/4885SLC6A4 4712/4885SLC6A3 4072/4885 |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | SLC6A2 2077/4885SLC6A4 1737/4885SLC6A3 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.